期刊
CANCER TREATMENT REVIEWS
卷 92, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2020.102137
关键词
MEK inhibitors; Mechanisms of Adaptive Resistance; Drug combination trials
类别
资金
- Ovarian Cancer Moon Shot Program at The University of Texas MD Anderson Cancer Center, Texas, USA
- U.S. Department of Defense Ovarian Cancer Research Program [W81XWH-19-1-0169]
The MAPK pathway is crucial in cancer development, and drugs targeting this pathway, especially MEK inhibitors, have shown promise. However, research and solutions regarding adaptive resistance mechanisms to MEK inhibitors are still challenging.
The mitogen-activated protein kinase (MAPK) pathway plays a vital role in cellular processes such as gene expression, cell proliferation, cell survival, and apoptosis. Also known as the RAS-RAF-MEK-ERK pathway, the MAPK pathway has been implicated in approximately one-third of all cancers. Mutations in RAS or RAF genes such as KRAS and BRAF are common, and these mutations typically promote malignancies by over-activating MEK and ERK downstream, which drives sustained cell proliferation and uninhibited cell growth. Development of drugs targeting this pathway has been a research area of great interest, especially drugs targeting the inhibition of MEK. In vitro and clinical studies have shown promise for certain MEK inhibitors (MEKi) , and MEKi have become the first treatment option for certain cancers. Despite promising results, not all patients have a response to MEKi, and mechanisms of resistance typically arise in patients who do have a positive initial response. This paper summarizes recent developments regarding MEKi, the mechanisms of adaptive resistance to MEKi, and the potential solutions to the issue of adaptive MEKi resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据